share_log

Asher Bio Announces Clinical Supply Agreement With AstraZeneca To Enable Evaluation Of Etakafusp Alfa In Combination With Rilvegostomig In A Global Phase 1b/2 Study In Non-Small Cell Lung Cancer

Benzinga ·  Jan 7 21:02

– Clinical supply agreement with AstraZeneca for global Phase 1b/2 study to evaluate the safety and early efficacy of etakafusp alfa (AB248) in combination with rilvegostomig as a first-line treatment in patients with advanced or metastatic NSCLC –

Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced an agreement with AstraZeneca (NASDAQ:AZN) to supply etakafusp alfa (formerly known as AB248), Asher Bio's investigational CD8+ T cell targeted interleukin-2 (IL-2) immunotherapy, to be evaluated in combination with rilvegostomig, AstraZeneca's investigational PD-1/TIGIT immuno-oncology bispecific antibody, in patients with advanced or metastatic NSCLC.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment